ストックスクリーナーアプリを入手
26.18
0.00%
0.00
前日終値:
$26.18
開ける：
$25.25
24時間の取引高:
206.38K
Relative Volume:
66.00
時価総額：
$835.43M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$24.71
$28.43
1週間の範囲:
$24.71
$28.43
52週間の値動き範囲:
$24.71
$28.43
Spyglass Pharma Inc Stock (SGP) Company Profile
Compare SGP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
26.18 | 842.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spyglass Pharma Inc (SGP) 最新ニュース
Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering - Legal Desire Media and Insights
SpyGlass Pharma Closes $172.5 Million IPO - marketscreener.com
SpyGlass Pharma closes $172.5 million IPO on NASDAQ - Investing.com
Late-stage drugmaker SpyGlass Pharma raises $172.5M in IPO - stocktitan.net
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO - TipRanks
SpyGlass Pharma Raises $150 Million in Initial Public Offering - VisionMonday.com
SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One - Smartkarma
SpyGlass Pharma, Developer of Long-Acting Ocular Drug-Delivery Implants for Glaucoma and Other Chronic Eye Conditions, Files for Nasdaq Global Select Market IPO - TradingView
Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO - bloomberg.com
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts - intellectia.ai
Spyglass Pharma shares surge 50% in Nasdaq debut By Investing.com - Investing.com Canada
Eye care firm SpyGlass Pharma soars 50% after $150 million IPO - MSN
SpyGlass Pharma Rings the Opening Bell - Nasdaq
SpyGlass Pharma Raises $150 Million in IPO for Eye Condition Treatments - intellectia.ai
SpyGlass Pharma raises $150 million in IPO priced at $16 per share - Investing.com
SpyGlass Pharma Prices $150 Million IPO - marketscreener.com
SGP IPO NewsChronic eye condition biotech SpyGlass Pharma prices IPO at $16 midpoint - renaissancecapital.com
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO - Wilson Sonsini
SpyGlass Pharma prices IPO at $16 per share, raising $150 million - Investing.com Nigeria
SpyGlass Pharma announces pricing of IPO at $16.00 per share - marketscreener.com
Spyglass Pharma Announces Pricing Of IPO At $16.00 Per Share - TradingView
Late-stage biopharma SpyGlass Pharma to debut on Nasdaq after $150M IPO - stocktitan.net
SpyGlass Pharma Announces Pricing of Initial Public Offering - GlobeNewswire
IPO Rating: Spyglass Pharma Inc. - Smartkarma
SpyGlass Pharma Sets Terms for IPO as Ophthalmology-Focused Biotech Advances Sustained-Release Platform - Smartkarma
SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week - Smartkarma
First Look | SpyGlass Pharma (Pending:SGP) - Seeking Alpha
SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care - Smartkarma
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System - GlobeNewswire
SpyGlass Pharma Files $100M IPO - Orange County Business Journal
Eye Care-Focused Biopharma Firm SpyGlass Files for US IPO - bloomberg.com
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer - GlobeNewswire
SpyGlass Pharma Announces Positive 36-Month First-in-Human - GlobeNewswire
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months - Ophthalmology Times
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial - GlobeNewswire
SpyGlass Pharma Raises $75M Series D Round - Orange County Business Journal
SpyGlass Pharma secures $75m for ophthalmic drug delivery platform - Pharmaceutical Technology
SpyGlass Pharma raises $75M for drug delivery platform - Drug Delivery Business
SpyGlass Pharma Presents 18-Month Data Demonstrating - GlobeNewswire
SpyGlass Pharma Completes Enrollment in Phase I/II Study of - GlobeNewswire
SpyGlass Posts Positive Early Data in IOL Clinical Trial - Orange County Business Journal
SpyGlass Pharma unveils 1-year data of drug delivery platform implanted during routine cataract surgery in patients diagnosed with glaucoma - Ophthalmology Times
SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases - PRWeb
SpyGlass Pharma releases 6-month data from first-in-human trial for glaucoma - Eyes On Eyecare
Spyglass Pharma Inc (SGP) 財務データ
Spyglass Pharma Inc (SGP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.10%
7.16%
大文字化:
|
ボリューム (24 時間):